Skip to content
Screener

Arbutus Biopharma Corporation ABUS Interest Income

Interest Income at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$16.87M+75.4%
ALN
Alnylam PharmaceuticalsALNY
$28.14M+2.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$2.65M-39.9%
Assembly Biosciences logo
Assembly BiosciencesASMB
$2.29M+104%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$8.97M-16.9%
Prime Medicine logo
Prime MedicinePRME
$788K+6.1%

Other financials

Income statement

See full
Revenue$1.0M-90.6%
Operating income-$6.0M-501%
Net income-$5.1M-304%
EPS (diluted)-$0.03-400%

Balance sheet

See full
Cash & equivalents$19.2M-48.8%
Total debt$514.0K-52.8%
Total equity$258.7M+212%
Total assets$274.0M+165%

Cash flow

See full
Operating cash flow-$6.0M+61.8%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$906.7M+41.2%
Enterprise value$888.04M+46.6%
P/E5.9×—
P/S5×-36.7×

Profitability

See full
Operating margin82%+44.9pp
Net margin84.2%+46.6pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity89.6%+65.3pp
Debt / equity0×0.0×
Current ratio81.4×+60.9×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:31 AM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q3 2026
Accession
0001447028-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses6,9789,25117,19636,714
(Loss) income from operations(5,964)1,488162,944(24,211)
Other income
Interest income8421,0421,6572,239
Interest expense(18)(28)(35)(56)
Foreign exchange (loss) gain(3)21(14)25
Total other income8211,0351,6082,208
Net (loss) income$(5,143)$2,523$164,552$(22,003)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's interest income?
Arbutus Biopharma Corporation (ABUS) reported interest income of $842K in Q2 2026.
How has Arbutus Biopharma Corporation's interest income changed year-over-year?
Arbutus Biopharma Corporation's interest income decreased by 19.2% year-over-year, from $1.04M to $842K.
What is the long-term trend for Arbutus Biopharma Corporation's interest income?
Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's interest income has grown at a 137.9% compound annual growth rate (CAGR), from $127K to $4.07M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Arbutus Biopharma Corporation's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude